PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17032739-0 2006 Inhibition of RET tyrosine kinase by SU5416. Semaxinib 37-43 ret proto-oncogene Homo sapiens 14-17 17032739-4 2006 We found that SU5416 inhibits RET with similar potency, both in cell-free assays and in cells, thus causing proliferation arrest in oncogenic RET-transfected cells and in papillary thyroid carcinoma (PTC) cells expressing the RET/PTC1 oncogene, but not in RET-negative control cells. Semaxinib 14-20 ret proto-oncogene Homo sapiens 30-33 17032739-4 2006 We found that SU5416 inhibits RET with similar potency, both in cell-free assays and in cells, thus causing proliferation arrest in oncogenic RET-transfected cells and in papillary thyroid carcinoma (PTC) cells expressing the RET/PTC1 oncogene, but not in RET-negative control cells. Semaxinib 14-20 ret proto-oncogene Homo sapiens 142-145 17032739-4 2006 We found that SU5416 inhibits RET with similar potency, both in cell-free assays and in cells, thus causing proliferation arrest in oncogenic RET-transfected cells and in papillary thyroid carcinoma (PTC) cells expressing the RET/PTC1 oncogene, but not in RET-negative control cells. Semaxinib 14-20 ret proto-oncogene Homo sapiens 142-145 17032739-4 2006 We found that SU5416 inhibits RET with similar potency, both in cell-free assays and in cells, thus causing proliferation arrest in oncogenic RET-transfected cells and in papillary thyroid carcinoma (PTC) cells expressing the RET/PTC1 oncogene, but not in RET-negative control cells. Semaxinib 14-20 ret proto-oncogene Homo sapiens 142-145 17032739-5 2006 SU5416 inhibited RET-mediated signaling through the extracellular signal regulated kinase (ERK) and JNK pathways. Semaxinib 0-6 ret proto-oncogene Homo sapiens 17-20 23960782-0 2012 The immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties. Semaxinib 37-46 ret proto-oncogene Homo sapiens 94-118 16849418-3 2006 OBJECTIVE: The objective of the study was to evaluate the efficacies of the recently developed kinase inhibitors SU11248, SU5416, and SU6668 in inhibition of RET/PTC. Semaxinib 122-128 ret proto-oncogene Homo sapiens 158-161 16849418-3 2006 OBJECTIVE: The objective of the study was to evaluate the efficacies of the recently developed kinase inhibitors SU11248, SU5416, and SU6668 in inhibition of RET/PTC. Semaxinib 122-128 ret proto-oncogene Homo sapiens 162-165 16849418-6 2006 RESULTS: An in vitro kinase assay revealed that SU5416, SU6668, and SU11248 inhibited phosphorylation of the synthetic tyrosine kinase substrate peptide E4Y by RET/PTC3 in a dose-dependent manner with IC(50) of approximately 944 nm for SU5416, 562 nm for SU6668, and 224 nm for SU11248. Semaxinib 48-54 ret proto-oncogene Homo sapiens 160-163 16849418-6 2006 RESULTS: An in vitro kinase assay revealed that SU5416, SU6668, and SU11248 inhibited phosphorylation of the synthetic tyrosine kinase substrate peptide E4Y by RET/PTC3 in a dose-dependent manner with IC(50) of approximately 944 nm for SU5416, 562 nm for SU6668, and 224 nm for SU11248. Semaxinib 236-242 ret proto-oncogene Homo sapiens 160-163 11418488-0 2001 Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Semaxinib 80-86 ret proto-oncogene Homo sapiens 45-69 11418488-1 2001 The small molecule receptor tyrosine kinase (RTK) inhibitor SU5416 targets the vascular endothelial growth factor receptor 2 and the stem cell factor receptor c-kit. Semaxinib 60-66 ret proto-oncogene Homo sapiens 19-43 11418488-1 2001 The small molecule receptor tyrosine kinase (RTK) inhibitor SU5416 targets the vascular endothelial growth factor receptor 2 and the stem cell factor receptor c-kit. Semaxinib 60-66 ret proto-oncogene Homo sapiens 45-48 11418488-6 2001 This is the first report of a stable remission achieved after administration of the RTK inhibitor SU5416 in a patient with AML relapse. Semaxinib 98-104 ret proto-oncogene Homo sapiens 84-87